BIOA
NASDAQBioAge Labs Inc.
$17.03-0.21 (-1.25%)
News25/Ratings12
News · 26 weeks59-44%
2025-11-022026-04-26
Mix3090d
- Insider11(37%)
- SEC Filings9(30%)
- Analyst4(13%)
- Other4(13%)
- Offering1(3%)
- Earnings1(3%)
Latest news
25 items- INSIDERChief Financial Officer Goldstein Dov A Md exercised 3,542 shares at a strike of $4.38, increasing direct ownership by 11% to 36,575 units (SEC Form 4)4 - BioAge Labs, Inc. (0001709941) (Issuer)
- SECSEC Form DEFA14A filed by BioAge Labs Inc.DEFA14A - BioAge Labs, Inc. (0001709941) (Filer)
- SECSEC Form DEF 14A filed by BioAge Labs Inc.DEF 14A - BioAge Labs, Inc. (0001709941) (Filer)
- PRBioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP120 mg and newly announced 60 mg once-daily doses each achieved ≥85% median hsCRP reductions in participants with obesity and elevated baseline inflammation BGE-102 was well tolerated across all dose levels Phase 2 proof-of-concept trial in cardiovascular risk planned to initiate mid-2026, with results anticipated by end of year Phase 1b/2a proof-of-concept trial in diabetic macular edema (DME) planned to initiate mid-2026, with results anticipated mid-2027 BioAge to host conference call and webcast today at 8:00 AM ET to discuss BGE-102 results EMERYVILLE, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge" or the "Company"), a clinical-stage biopharm
- PRBioAge Labs to Present at 25th Annual Needham Virtual Healthcare ConferenceEMERYVILLE, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will present at the 25th Annual Needham Virtual Healthcare Conference taking place April 13–16, 2026. Kristen Fortney, PhD, CEO and co-founder, is scheduled to participate in a fireside chat on Thursday, April 16 from 3:00 PM to 3:30 PM EDT. Kristen Fortney, Dov Goldstein, MD, CFO, and BJ Sullivan, PhD, Chief Strategy Officer, will participate in one-on-one meetings. To access the live webcast of the p
- INSIDERSEC Form 4 filed by Rubin Paul D4 - BioAge Labs, Inc. (0001709941) (Issuer)
- SECSEC Form 144 filed by BioAge Labs Inc.144 - BioAge Labs, Inc. (0001709941) (Subject)
- ANALYSTNeedham initiated coverage on BioAge Labs with a new price targetNeedham initiated coverage of BioAge Labs with a rating of Buy and set a new price target of $50.00
- SECSEC Form S-3ASR filed by BioAge Labs Inc.S-3ASR - BioAge Labs, Inc. (0001709941) (Filer)
- SECSEC Form S-8 filed by BioAge Labs Inc.S-8 - BioAge Labs, Inc. (0001709941) (Filer)
- SECSEC Form 10-K filed by BioAge Labs Inc.10-K - BioAge Labs, Inc. (0001709941) (Filer)
- SECBioAge Labs Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - BioAge Labs, Inc. (0001709941) (Filer)
- PRBioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025Positive interim Phase 1 data for BGE-102, a potent, structurally novel, orally available, brain-penetrant small-molecule NLRP3 inhibitor, demonstrating potential best-in-class reductions in inflammatory biomarkers of cardiovascular risk; Phase 2a proof-of-concept trial planned to initiate in 1H 2026 Indication expansion for BGE-102 into ophthalmology; Phase 1b/2a proof-of-concept trial in diabetic macular edema planned to initiate mid-2026 Completed upsized follow-on public offering of $132.3 million with full exercise of the underwriters' overallotment option in February 2026 EMERYVILLE, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", "the Company"), a cl
- PRNew data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congressSTOCKHOLM, March 23, 2026 /PRNewswire/ -- BioArctic's AB (publ) (NASDAQ:BIOA) partner Eisai presented new data at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD™), held in Copenhagen, Denmark March 17-21. BioArctic also held an oral presentation on lecanemab and a poster presentation relating to exidavnemab. Eisai presented new real-world findings from an analysis of long-term treatment persistence among early Alzheimer's disease patients in the United States receiving intravenous (IV) lecanemab. Based on data from the PurpleLab®[1] claims database, the analysis showed that most patients continued lecanemab therapy after
- INSIDERChief Medical Officer Rubin Paul D exercised 7,433 shares at a strike of $4.77 and sold $150,890 worth of shares (7,433 units at $20.30) (SEC Form 4)4 - BioAge Labs, Inc. (0001709941) (Issuer)
- INSIDERChief Financial Officer Goldstein Dov A Md exercised 3,542 shares at a strike of $4.38, increasing direct ownership by 12% to 33,033 units (SEC Form 4)4 - BioAge Labs, Inc. (0001709941) (Issuer)
- SECSEC Form 144 filed by BioAge Labs Inc.144 - BioAge Labs, Inc. (0001709941) (Subject)
- ANALYSTOppenheimer initiated coverage on BioAge Labs with a new price targetOppenheimer initiated coverage of BioAge Labs with a rating of Outperform and set a new price target of $60.00
- INSIDERSEC Form 4 filed by Chief Medical Officer Rubin Paul D4 - BioAge Labs, Inc. (0001709941) (Issuer)
- INSIDERSEC Form 4 filed by Chief Operating Officer Morgen Eric4 - BioAge Labs, Inc. (0001709941) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Goldstein Dov A Md4 - BioAge Labs, Inc. (0001709941) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Fortney Kristen4 - BioAge Labs, Inc. (0001709941) (Issuer)
- INSIDERSEC Form 4 filed by Principal Accounting Officer Barton Shane4 - BioAge Labs, Inc. (0001709941) (Issuer)
- PRBioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences ConferenceEMERYVILLE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference taking place February 25-26, 2026. Kristen Fortney, PhD, CEO and co-founder, is scheduled to participate in a fireside chat on Thursday, February 26 from 10:40 AM to 11:05 AM ET. Fortney and Dov Goldstein, MD, CFO, will participate in one-on-one meetings. To access the live webcast of the presentation, register here. Replay
- ANALYSTBioAge Labs upgraded by Jefferies with a new price targetJefferies upgraded BioAge Labs from Hold to Buy and set a new price target of $62.00